EMRELIS J Code: J9326

Drug & Product Overview

HCPCS Descriptor Injection, telisotuzumab vedotin-tllv, 1 mg

HCPCS Added Date January 1, 2026

Manufacturer Abbvie

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose

Dosage Form Injection, Powder, Lyophilized, For Solution

About EMRELIS

Emrelis is a medication aligned to the HCPCS J Code: J9326 for billing, pricing, and reimbursement purposes in the United States. Classified under Oncology, it is administered via the intravenous route and manufactured by Abbvie.

According to CMS Drug Use Information: This medication is used to treat a certain type of lung cancer (non-squamous non-small cell lung cancer-NSCLC). It works by slowing or stopping the growth of cancer cells.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
00074-1044-01	Emrelis	AbbVie Inc.	20	20 MG / 1 ML
00074-1055-01	Emrelis	AbbVie Inc.	100	100 MG / 1 ML

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

EMRELIS Pricing & Reimbursement

J9326 Private Payer Reimbursement

$149.78 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

EMRELIS Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 27.04%

Avg. Days to File 11.4days

Avg. Days to Pay 31.1days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J9326 claims analytics on FocalPoint →

EMRELIS CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

EMRELIS Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression

Frequently Asked Questions

Is there a manufacturer-published EMRELIS billing and coding guide?

Billing and coding information for EMRELIS can be found through Abbvie. Visit Here →

Is there an available EMRELIS patient assistance program?

EMRELIS patient assistance information can be found through AbbVie Inc.. Visit Here →

Where can I find EMRELIS prescribing information?

EMRELIS prescribing information can be found at the link below. Visit Here →

Where can I find EMRELIS side effect information?

EMRELIS side effect information can be found through MedlinePlus. Visit Here →

Does billing EMRELIS require JZ/JW wastage modifiers?

CMS does not include EMRELIS (J9326) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J9326. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.